Dr. Collins brings multi-disciplinary expertise in the design and construction of synthetic gene circuits and programmable cells
Cambridge, MA – January 11, 2019. Asimov, the synthetic biology company building a genetic design platform for molecular manufacturing and therapeutic applications, announced today it has appointed Dr. James J. Collins as its inaugural Scientific Advisory Board member.
Dr. Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT). He is a prolific bioengineer, having published more than 200 scientific papers and patents including the seminal synthetic biology publication, “Construction of a genetic toggle switch in Escherichia coli”. A recipient of numerous awards including a MacArthur Genius Award and a Rhodes Scholarship, Dr. Collins is an elected member of all three national academies: the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine.
“We are thrilled to have Jim join us, as he is quite simply one of the most influential and visionary bioengineers of all time,” said Alec Nielsen, Ph.D., Asimov co-founder and CEO. “He established the field of synthetic biology and has consistently driven the cutting edge across multiple scientific domains. Jim’s deep expertise in genetic circuit design, systems biology, and machine learning aligns perfectly with Asimov’s mission to build the world’s most powerful genetic design platform.”
Dr. Collins joins the 15-person synthetic biology company, headquartered in Cambridge, Massachusetts. The team also includes MIT professor Christopher Voigt, Boston University professor Douglas Densmore, and MIT Ph.D. Raja Srinivas as co-founders.
“I’m delighted to join Asimov, which is bridging the synthetic biology and machine learning domains,” said Dr. Collins. “To achieve true predictive design of biology, we require radical advances in both the computational and genetic engineering toolchains. I look forward to helping guide development of Asimov’s platform.”
ABOUT ASIMOV. Asimov is a synthetic biology company combining genetic engineering, artificial intelligence, and design automation. Asimov’s interdisciplinary team is building an advanced genetic design platform for next-generation therapeutics and molecular manufacturing. For more information visit www.asimov.io.